Pelthos Therapeutics Restates Q1 2026 Financials Over Convertible Debt Valuation

What Happened
Pelthos Therapeutics (PTHS) announced that on August 12, 2026 its Audit Committee, with management, concluded that the Company’s previously issued condensed consolidated financial statements for the quarter ended March 31, 2026 should no longer be relied upon. The Company identified a misapplication of ASC 820 (Fair Value Measurements) related to certain Level 3 fair value inputs for convertible debt tied to a subordination agreement entered in January 2026 (including extended payoff terms and a conversion rate reset). Pelthos will restate the Q1 2026 Form 10‑Q by filing Amendment No. 1.

Key Details

• Audit Committee conclusion date: August 12, 2026; 8‑K filed August 13, 2026.
• Restatement impacts to the March 31, 2026 condensed balance sheet: $15.8 million increase in the fair value of convertible debt (liabilities); $1.0 million reduction in accumulated other comprehensive income; $14.8 million increase in accumulated deficit (stockholders’ equity).
• Restatement impacts to the statement of operations: $14.8 million increase in non‑cash expense for change in fair value of convertible debt (other expense/income) and a $1.0 million decrease in fair‑value change due to instrument credit risk recorded in other comprehensive loss — affecting net loss and net loss per share (basic and diluted).
• No effect on cash, liquidity, revenues, operating expenses, or operating loss (the fair‑value change was recorded in other income/expense).

Why It Matters
This restatement materially changes reported liabilities, equity and non‑cash expense for Q1 2026 and will increase reported net loss and reduce reported EPS for that period. Although the restatement does not affect cash or operating results, investors and analysts should not rely on the originally filed Q1 2026 financials and should review the forthcoming Form 10‑Q/A for updated figures and disclosures.